- Home
- SAND vs RDY Comparison
SAND vs RDY Comparison
Compare SAND & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- RDY
- Stock Information
- Founded
- SAND 2007
- RDY 1984
- Country
- SAND Canada
- RDY India
- Employees
- SAND N/A
- RDY N/A
- Industry
- SAND
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- SAND
- RDY Health Care
- Exchange
- SAND NYSE
- RDY Nasdaq
- Market Cap
- SAND 1.9B
- RDY 2.1B
- IPO Year
- SAND N/A
- RDY N/A
- Fundamental
- Price
- SAND $7.49
- RDY $13.17
- Analyst Decision
- SAND Buy
- RDY Buy
- Analyst Count
- SAND 3
- RDY 1
- Target Price
- SAND $9.42
- RDY $17.00
- AVG Volume (30 Days)
- SAND 4.2M
- RDY 1.9M
- Earning Date
- SAND 05-01-2025
- RDY 05-06-2025
- Dividend Yield
- SAND 0.70%
- RDY 3.63%
- EPS Growth
- SAND N/A
- RDY 2.68
- EPS
- SAND 0.05
- RDY 0.75
- Revenue
- SAND $176,283,000.00
- RDY $3,637,607,642.00
- Revenue This Year
- SAND $12.83
- RDY $17.23
- Revenue Next Year
- SAND $12.67
- RDY $9.19
- P/E Ratio
- SAND $155.90
- RDY $17.92
- Revenue Growth
- SAND N/A
- RDY 14.74
- 52 Week Low
- SAND $4.92
- RDY $12.50
- 52 Week High
- SAND $7.74
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- SAND 70.99
- RDY 45.70
- Support Level
- SAND $7.37
- RDY $13.10
- Resistance Level
- SAND $7.74
- RDY $13.85
- Average True Range (ATR)
- SAND 0.21
- RDY 0.13
- MACD
- SAND 0.08
- RDY 0.03
- Stochastic Oscillator
- SAND 82.29
- RDY 48.88
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.